Study Shows Multiple Infliximab Biosimilar Switches are Effective for Patients with IBD
April 21st 2023A study in Scotland found that multiple successive changes from originator infliximab to biosimilars effective and safe for patients with irritable bowel disease (IBD), irrespective of the number of switches (single, double, and triple).
Does Tirzepatide's Benefits in Patients with Type 2 Diabetes Make The Price Worth It?
April 12th 2023Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?